Shield Therapeutics PLC Director/PDMR Shareholding (1839J)
15 August 2019 - 7:17PM
UK Regulatory
TIDMSTX
RNS Number : 1839J
Shield Therapeutics PLC
15 August 2019
Shield Therapeutics plc
("Shield" or the "Company")
Director / PDMR Shareholding
London, UK, 15 August 2019, Shield Therapeutics plc (LSE:STX), a
commercial stage, pharmaceutical company with an initial focus on
addressing iron deficiency, announces that James Karis, Chairman of
the Company, has acquired 75,000 Ordinary Shares in the Company on
13 August 2019 for consideration of GBP1.78 per Ordinary Share.
Following the transaction, Mr Karis holds 161,667 shares,
representing 0.001% of the Company's issued share capital.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name James Karis
------------------------------------------------------- --------------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------------------------------------------
a) Position/status Chairman
------------------------------------------------------- --------------------------------------------------------
b) Initial notification/ Amendment Initial Notification
------------------------------------------------------- --------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
-----------------------------------------------------------------------------------------------------------------
a) Name Shield Therapeutics plc
------------------------------------------------------- --------------------------------------------------------
b) LEI 213800G74QWY15FC3W71
------------------------------------------------------- --------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Ordinary shares of 1.5p each in the capital of the
instrument Company
Identification code ISIN of Ordinary Shares: GB00BYV81293
------------------------------------------------------- --------------------------------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares
------------------------------------------------------- --------------------------------------------------------
c) Price(s) and volume(s) GBP1.78 per Ordinary Share
Volumes: 75,000
------------------------------------------------------- --------------------------------------------------------
d) Aggregated information 75,000
GBP133,500
* Aggregated volume
* Price
------------------------------------------------------- --------------------------------------------------------
e) Date of the transaction 13 August 2019
------------------------------------------------------- --------------------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
------------------------------------------------------- --------------------------------------------------------
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive
Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial Officer
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd +44 (0)20 7220 0500
Geoff Nash /Matt Radley/ Alice
Lane
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584
Paul McManus / Lianne Cawthorne 391 303
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, specialty
pharmaceutical company delivering innovative pharmaceuticals to
address patients' unmet medical needs. The Company's clear purpose
is to help its patients become people again, by enabling them to
enjoy the things that make the difference in their everyday lives.
The Group has a marketed product, Feraccru(R)/Accrufer(R), for the
treatment of iron deficiency in adults which has exclusive IP
rights until the mid-2030s. Feraccru(R)/Accrufer(R) is approved by
the FDA, EMA and Swiss Medic for the treatment of iron deficiency
in adults and is commercialised in the European Union by Norgine
BV, with a US commercialisation partner currently being selected.
For more information please visit www.shieldtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements. These forward-looking statements are based on
management's current expectations and include statements related to
the commercial strategy for Feraccru(R)/Accrufer(R). These
statements are neither promises nor guarantees, but involve known
and unknown risks and uncertainties, many of which are beyond our
control, that may cause actual results, performance or achievements
to be materially different from management's expectations expressed
or implied by the forward-looking statements, including, but not
limited to, risks associated with, the Group's business and results
of operations, competition and other market factors. The
forward-looking statements made in this press release represent
management's expectations as of the date of this press release, and
except as required by law, the Group disclaims any obligation to
update any forward-looking statements contained in this release,
even if subsequent events cause our views to change.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKELBFKVFFBBQ
(END) Dow Jones Newswires
August 15, 2019 05:17 ET (09:17 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024